Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Foslinanib - TaiRx

Next Previous
Drug Profile

Foslinanib - TaiRx

Alternative Names: CVM-1118; TRX-818

Latest Information Update: 04 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TaiRx
  • Class Antineoplastics; Quinolines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Growth inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer; Neuroendocrine tumours
  • No development reported Cancer; Lymphoma; Solid tumours

Most Recent Events

  • 31 Jan 2025 Foslinanib receives Orphan Drug status for Neuroendocrine tumours in USA
  • 13 Sep 2024 Efficacy, pharmacokinetics and adverse event data from a phase II trial in Neuroendocrine-tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 31 May 2024 Efficacy, adverse events and pharmacokinetics data from a phase II trial in Liver cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top